Lytix is exploiting its proprietary technology by creating a pipeline of small molecule compounds in its chosen application areas. Depending on the application and potential, these compounds will either be out-licensed at an early preclinical stage or taken through to full development and commercialisation in collaboration with carefully selected partners.

Lytix is interested in evaluating in-licensing opportunities that have a clear strategic fit with our portfolio.
We also actively consider M&A opportunities as a means of accelerating growth.

Details and further information:

Please contact Director of Business Development, Anders Fugelli, PhD – anders.fugelli"at"lytixbiopharma.com / cell phone +47 924 81 432